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Abstract: Challenges in obtaining tissue specimens from patients with brain tumours limit the diagnosis
and molecular characterisation and impair the development of better therapeutic approaches. The anal-
ysis of cell-free tumour DNA in plasma (considered a liquid biopsy) has facilitated the characterisation
of extra-cranial tumours. However, cell-free tumour DNA in plasma is limited in quantity and may not
reliably capture the landscape of genomic alterations of brain tumours. Here, we review recent work
assessing the relevance of cell-free tumour DNA from cerebrospinal fluid in the characterisation of brain
cancer. We focus on the advances in the use of the cerebrospinal fluid as a source of cell-free tumour DNA
to facilitate diagnosis, reveal actionable genomic alterations, monitor responses to therapy, and capture
tumour heterogeneity in patients with primary brain tumours and brain and leptomeningeal metastases.
Profiling cerebrospinal fluid cell-free tumour DNA provides the opportunity to precisely acquire and
monitor genomic information in real time and guide precision therapies.
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Challenges in obtaining tissue specimens from patients with brain tumours limits diagnosis and 
molecular characterisation and impairs the development of better therapeutic approaches. The analysis 
of cell-free tumour DNA in plasma (considered a liquid biopsy) has facilitated the characterisation of 
extra-cranial tumours. However, cell-free tumour DNA in plasma is limited in quantity and may not 
reliably capture the landscape of genomic alterations of brain tumours. Here, we review recent work 
assessing the relevance of cell-free tumour DNA from cerebrospinal fluid in the characterisation of brain 
cancer. We focus on the advances in the use of the cerebrospinal fluid as a source of cell-free tumour 
DNA to facilitate diagnosis, reveal actionable genomic alterations, monitor responses to therapy, and 
capture tumour heterogeneity in patients with primary brain tumours and brain and leptomeningeal 
metastases. Profiling cerebrospinal fluid cell-free tumour DNA provides the opportunity to precisely 
acquire and monitor genomic information in real time and guide precision therapies.  
Keywords: Cerebrospinal fluid, circulating cell-free tumour DNA, genomic characterisation, 
glioblastoma, brain metastasis, liquid biopsy, brain cancer.  
 
KEY MESSAGE  
Challenges in systematically obtaining tumour tissue from brain primary tumours and metastases 
preclude their molecular characterisation and monitoring over time. Profiling cerebrospinal fluid cell-
free tumour DNA provides an opportunity for precisely acquiring genomic information with the potential 







Genomic characterisation of tumour tissue has been established as crucial for state-of-the-art diagnostic 
and therapeutic approaches to cancer. However, characterisation of cancer is challenged by constitutive 
and evolving intra-tumour and inter-lesion heterogeneity which requires thorough and continuous 
analysis of genomic complexity over time. This is particularly relevant in brain malignancies where the 
genomic landscape changes in response to treatment or during relapse, and can differ from the primary 
extra-cranial lesion in the case of brain metastases. Yet, obtaining samples for characterisation and 
correct diagnosis can be difficult in brain cancer patients. The anatomical location of the tumour limits 
access due to the risk and complexity of intracranial surgical procedures.  
Invasive surgical procedures have been the cornerstone treatment and a diagnostic tool in patients with 
primary brain tumours and in selected patients with brain metastasis. However, collecting tumour tissue 
from central nervous system (CNS) malignancies is complex, can be risky, and sometimes unfeasible, at 
least with purely diagnostic intent. Surgery has a role in improving disease control in patients with 
primary tumours or with a single, resectable brain metastasis, whereas patients with disseminated 
systemic disease are frequently not candidates for routine neurosurgical procedures [1, 2]. Moreover, 
specimens may be small and not representative hampering correct diagnosis or even necessitating 
multiple surgical samplings to clarify final pathological diagnosis. In addition, the surgical intervention 
strategy and assessment of the surgical risk-benefit balance depend on the tumour prognosis. This 
implies that an intraoperative histologic diagnosis may be required possibly delaying the surgical 
procedure. Repeat surgical interventions may be needed to differentiate tumour pseudoprogression 
induced by treatment from true relapse. The challenges in obtaining tumour tissue have led physicians 
to rely on primary archival tumour specimens. Thus, in some cases, therapies for brain cancer are 
selected based on the molecular characteristics of the primary tumour which can differ from the current 
tumour manifestation [3, 4].  
Plasma cell-free circulating tumour DNA (ctDNA) has been used as a “liquid biopsy” in the context of 
tumour genomic characterisation [5-12]. ctDNA is the fraction of the total cell-free DNA that is derived 
from tumour cells and can be defined by the presence of genomic alterations. ctDNA detected in plasma 
has shown promise in characterising tumours and allowing patients and their cancers to be monitored 
over time. Analyses of mutations in plasma ctDNA have demonstrated high concordance with genomic 





However, in the context of primary brain tumours and brain metastasis, plasma ctDNA has been shown 
to be in low abundance and present in a limited number of patients [8, 13-16]. Importantly, the 
cerebrospinal fluid (CSF) is in intimate contact with brain malignancies and has been recently proven to 
contain ctDNA. The CSF space involves the intracerebral ventricles, subarachnoid spaces of the spine and 
brain (cisterns and sulci), and the central spinal cord canal. The CSF is renewed 3-5 times daily and is 
produced by the choroid plexus. The CSF circulates in a craniocaudal direction from ventricles to spinal 
subarachnoid space from where it is removed via craniocaudal lymphatic routes and the venous 
system[17]. The CSF space is separated from the vascular system by the blood-CSF barrier, while the 
blood-brain barrier is located between the brain parenchyma and the vascular system[18]. 
CSF has been explored as a source of ctDNA for precisely characterising brain cancers. Studies reported 
prior to the era of high-throughput sequencing showed that some molecular alterations or gene 
mutations can be detected in the DNA present in the CSF of patients with brain tumours [19-24]. 
Importantly, massively parallel sequencing methods have recently been used to analyse cell-free tumour 
DNA from CSF to comprehensively characterise somatic alterations including gene mutations and copy 
number alterations [15, 25-29] (Table 1).   
DNA was isolated from CSF (ranging from 0.75 - 10 ml) usually obtained from a lumbar puncture and 
DNA sequencing (i.e. droplet digital PCR, targeted sequencing, whole exome sequencing, or shallow 
whole genome sequencing) allowed the identification of ctDNA. Notably, CSF ctDNA enabled 
identification of genomic alterations in patients with systemic metastatic burden including brain 
metastasis, or disease restricted to the brain (primary tumours and brain metastasis) [15, 25-27]. Higher 
grade brain tumours were more likely to exhibit detectable CSF ctDNA than lower grade ones [26] and, 
in some cases, the distance of the tumour to CSF spaces could determine the amount of CSF ctDNA[27].  
Here, we focus on the studies related to ctDNA obtained from CSF. Nowadays, the CSF liquid biopsy is 
increasingly allowing molecular diagnoses, providing information on prognosis, facilitating the 
identification of new actionable genomic alterations, aiding in monitoring response to therapy, and 
allowing deconvolution of tumour heterogeneity in patients with CNS cancer (Figure 1). 






Primary brain tumours encompass a large variety of lesions with diverse natural course, response to 
treatment, and prognosis. The histological grade and molecular genetic make-up determine prognosis, 
with median overall survivals ranging from less than 1 year (e.g. in glioblastoma of the elderly) to long-
term survival including cures (e.g. pilocytic astrocytoma and other rare circumscribed lesions). The 
clinical hallmark of glioblastoma is aggressive growth, local invasiveness and inexorable recurrence [30-
32]. In recent years, the development of novel sequencing technologies and DNA methylation profiling 
coupled to bioinformatics tools has yielded an unparalleled, comprehensive view of the genome and 
epigenome of brain tumours [33-36].  
The 2016 update of the WHO classification incorporated well established molecular parameters into the 
classification of brain tumours, specifically gliomas. The analysis of the CSF ctDNA of a cohort of diffuse 
gliomas indicated that they could be subtyped by analysing the IDH1 and IDH2, ATRX, TP53, TERT, H3F3A 
and HIST1H3B mutational status, facilitating the classification of diffuse gliomas and providing 
prognostic information [28]. Moreover, the presence of mutations in the TERT promoter found in CSF 
ctDNA correlated with outcome [37]. In the case of diffuse midline gliomas, the detection of H3F3A and 
HIST1H3B mutations in the CSF could confirm diagnosis [28]. This is of major relevance since the 
anatomical location of this type of tumours increases the risk of obtaining surgical specimens.  
CSF ctDNA was detected in a large proportion of patients with brain primary tumours (Table 1). 
However, CSF ctDNA is not found in all brain tumours. For example, in some low grade gliomas, CSF 
ctDNA was not detected or was not informative [28]. Technological advances may improve sequencing 
sensitivity in the future, thus reducing the number of non-informative cases.  
Therapeutic considerations 
ctDNA diagnostic applications with potential therapeutic implications remain limited for adult patients 
with primary brain tumours. The most relevant biomarker for glioblastoma in terms of choice of therapy 
remains promoter methylation of the MGMT gene [38]. Efforts at the detection of MGMT promoter 
methylation in CSF of glioma patients showed higher sensitivity than in plasma [39]. Future applications 
with therapeutic impact are likely to include the monitoring of EGFRvIII and amplified EGFR in patients 
undergoing EGFR targeted therapy [40]. The evaluation of ctDNA during the follow-up of patients and 







Brain metastases from solid tumours are more frequent than primary brain tumours. They may occur in 
20-40% of advanced stage cancers, particularly in lung cancer, breast cancer and melanoma [41-43]. 
Recent reports on the branched evolution of cancer at different sites including metastasis to the brain 
have reinforced the need of sequential molecular profiling across the disease trajectory [4, 44]. Brain 
metastases exhibit different genomic alterations than the primary extra-cranial tumours [4] indicating 
that the brain lesion-specific genomic alterations should be identified to select the optimal therapeutic 
approach [4, 45]. CSF ctDNA and not plasma ctDNA can be a good surrogate marker in such situations 
since ctDNA from brain lesions is enriched in the CSF. 
Trunk mutations, present in all cancer cells, as well as private genomic alterations, present in just a 
subpopulation of cells or in specific metastatic lesions, can be identified in the CSF [15, 27]. This allows 
opportunities for deconvolving tumour heterogeneity. CSF and plasma ctDNA were compared in a series 
of samples that included multiregional metastatic sites from postmortem specimens of patients with 
disseminated breast cancers including brain metastases [15]. For example, mutations found in the CSF 
ctDNA allowed to discern the origin of leptomeningeal and brain metastasis implants separately in a 
patient with Li Fraumeni syndrome and two concurrent tumours, a metastatic breast cancer and 
esthesioneuroblastoma [15]. CSF ctDNA analysis captured trunk mutations and, importantly, private 
mutations to the brain and to the meningeal deposits. These observations highlight the potential 
applications of CSF ctDNA to complement diagnosis of brain metastasis. 
Therapeutic considerations  
Several targeted therapeutic agents have demonstrated clinical activity against established brain 
metastases [46-55] and monitoring actionable mutations and therapy resistance using CSF ctDNA 
appears to be an application of CSF-based liquid biopsies that could be close to clinical practice. 
First (erlotinib and gefitinib) and second-generation (afatinib) epidermal growth factor receptor (EGFR) 
tyrosine kinase inhibitors (TKI) have shown activity against brain metastasis from non-small cell lung 
cancers (NSCLC) that harbour EGFR mutations [56-58]. A number of third-generation EGFR TKI that also 
target mutant EGFR T790M, which confers therapeutic resistance, are in various phases of clinical 
investigation to target brain metastases (osimertinib, rociletinib, ASP-8273, HM-61713). In anaplastic 





potency such as alectinib and ceritinib have apparently superior CNS penetration compared with 
crizotinib and share significant therapeutic potential [53-55]. Breast cancer studies have focused 
primarily on targeted therapies (e.g., lapatinib, pertuzumab, ado-trastuzumab emtansine (T-DM1)) used 
for HER2-positive cancers [51, 52, 59, 60]. In patients with melanoma and brain metastases, substantial 
clinical activity has been observed with BRAF and MEK inhibitors, e.g., dabrafenib plus trametinib [49, 
61], resulting in an intracranial response rate of nearly 60% [61]. Ongoing clinical trials exploit the 
cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) and programmed death 1 (PD-1) pathways as 
target for immune checkpoint inhibitor therapy [50, 62]. Actionable genomic alterations with potential 
therapeutic implications have been identified in the CSF ctDNA [15, 25-27], including EGFR, ALK, HER2, 
BRAF-targetable kinases and others associated with DNA integrity such as BRCA1 and BRCA2 [63]. 
Analysis of CSF ctDNA has also shown gene mutations associated with therapy resistance [15, 27, 64]. 
Drug-resistance mutations in patients whose CNS disease progressed during TKI therapy (EGFR, ALK, 
HER2, or BRAF) were identified in CSF ctDNA in one-third of cases [27]. This included a NRAS G12R 
mutation in the CSF of a BRAF V600E–mutant (and NRAS-negative) melanoma; a PIK3CA H1047R 
mutation in the CSF of a HER2-amplified breast cancer patient, potentially associated with trastuzumab 
resistance; and an EGFR T790M mutation in the CSF of a patient with EGFR-mutant NSCLC who did not 
respond to a second-generation EGFR TKI [27]. ESR1 mutations can confer resistance to aromatase 
inhibitor therapy in advanced estrogen receptor (ER)-positive breast cancers, but not to fulvestrant [65, 
66]. A clinical trial is evaluating ESR1 mutations in plasma ctDNA to predict the efficacy of a change of 
the hormone therapy (aromatase inhibitor changed to fulvestrant) (ClinicalTrials.gov Identifier: 
NCT03079011). Translation of this type of clinical trial design to the setting of patients with brain 
metastasis is envisioned using liquid biopsies. In the context of multiple metastases and discordant 
clinico-radiological findings, analysing a single-lesion biopsy is inadequate in guiding the selection of 
targeted therapy [67]. Parallel analyses of serial CSF and plasma ctDNA samples may be warranted.  
Although the most common initial clinical presentation of metastatic HER2-positive breast cancer is with 
extra-cranial metastases, CNS progression occurs in a substantial proportion of patients during the 
course of the disease [68]. It has also been shown that extensive extra-CNS disease control, with HER2 
targeting, might drive high incidence of CNS progression [69, 70]. This situation remains a major 
challenge where genomic analysis of ctDNA in the CSF might allow interrogation of the molecular status 
of progressive CNS metastasis. For example, in a case vignette, CSF ctDNA analysis captured CNS 





plasma ctDNA profiling did not play a diagnostic role [15]. A HER2-positive metastatic breast cancer 
patient with divergent responses of brain metastases underwent autopsy. Copy number alteration 
testing of three spatially separated brain metastases, in addition to CSF ctDNA and plasma ctDNA 
sampling, showed ERBB2 amplification, a hallmark of HER2-positive breast cancer in CSF ctDNA and not 
in the plasma analysis [15]. 
Leptomeningeal metastases 
Diagnostic considerations 
Leptomeningeal metastasis, defined by the multifocal seeding of the leptomeninges by malignant 
cells, is a rare but often rapidly fatal manifestation of advanced cancer [71-73]. Diagnosing 
leptomeningeal metastasis relies on clinical symptomatology, MRI, and on detecting malignant cells in 
the CSF through CSF cytology. Its incidence is increasing and prognosis remains poor despite 
radiotherapy, systemic and intrathecal chemotherapy, and precision treatments in molecularly 
selected patients [71, 72].  
Two principal diagnostic applications of ctDNA studies in patients with leptomeningeal metastasis 
emerge: first, detecting CSF ctDNA in patients with leptomeningeal metastasis may complement 
diagnostic profiling in patients with negative cytology, second, identifying actionable genomic 
alterations in CSF ctDNA has the potential to define an optimal targeted therapy[15]. CSF ctDNA 
revealed mutations in 50% of patients with primary brain tumours despite their CSF being negative 
for malignant cells [27], further, among patients with brain metastases, somatic mutations were 
found in 100% of patients with positive cytology and in 25% of patients with negative cytology [27].  
A pivotal study compared CSF profiling with CSF cytology results in the same CSF extraction [15]. 
Analysis of three metastatic breast cancer patients with clinical signs and symptoms suggestive of 
leptomeningeal metastasis showed that CSF ctDNA analysis was more sensitive than cytology in 
detecting leptomeningeal metastasis, and leptomeningeal infiltration was confirmed during autopsy 
[15]. A molecular case report compared paired profiling of matched CSF ctDNA and plasma ctDNA from 
a patient with HER2-positive metastatic breast cancer. The patient developed CNS progression and 
leptomeningeal metastasis whereas the systemic extracranial metastases showed a clinical and 
radiological response to treatment with T-DM1 [74]. CSF ctDNA revealed an enrichment of ERBB2 





progression whereas decreasing mutant allelic fractions of selected mutations in plasma ctDNA likely 
reflected a partial clinical response in the extracranial compartment [74]. In metastatic melanoma 
spreading to the leptomeninges, CSF examination using PCR-based techniques has been successfully 
used for diagnosis and monitoring response to therapy based on the detection of driver mutations, e.g. 
affecting BRAF.   [64, 75].  
Further work is warranted to consolidate CSF ctDNA as a complementary tool for the diagnosis and 
characterization of leptomeningeal metastasis. Accordingly, the EANO ESMO guideline advises caution in 
over-interpreting ctDNA detected in CSF as a proof of leptomeningeal seeding. 
Therapeutic considerations 
Recent and ongoing studies address the role of CSF ctDNA in patients with EGFR-mutant NSCLC and 
leptomeningeal metastasis [27, 64]. Forty NSCLC patients with suspected leptomeningeal metastasis 
were profiled, including 35 patients with a confirmed leptomeningeal metastases [64]. EGFR T790M and 
MET amplification were detected in 21% and 39% in CSF ctDNA, respectively, suggesting a resistance 
profile to EGFR-TKI associated with leptomeningeal disease. The BLOOM study (ClinicalTrials.gov 
Identifier: NCT02228369) investigates osimertinib, an oral, irreversible third-generation EGFR TKI 
selectively active against the EGFR T790M resistance mutation [76]. Encouraging activity has been seen 
in patients with leptomeningeal metastasis from NSCLC and results of EGFR mutant ctDNA analyses are 
being awaited (ClinicalTrials.gov Identifier: NCT02228369) [77]. Thus, ctDNA analysis should be 
considered for the EGFR and T790M status in the CSF at diagnosis and in case of suspicion of progression 
of NSCLC leptomeningeal metastases to guide the therapeutic decision. 
Road to clinical practice 
To integrate the assessment of ctDNA obtained from CSF liquid biopsies into current standards of care, 
several questions and controversies have to be addressed. For almost all primary brain tumours, extent 
of resection is an important prognostic factor. Thus, situations where a surgical intervention is not an 
option, but a diagnosis would still be welcome, are rare. These might include patients with major 
comorbidities thought to be at high risk of complications, e.g., those with high bleeding risk for various 
reasons. Furthermore, there are instances where initial stereotactic biopsies of brain lesions are not 
informative and where non-neoplastic lesions, e.g., neuroinflammatory or neuroinfectious diseases are 





ctDNA may greatly aid in further management. Furthermore, DNA methylation profiling may represent a 
novel approach that will undoubtedly also be explored for confirming tumour diagnoses from small 
tissue samples, including CSF [36]. Future studies will also need to determine in how far serial 
assessments of ctDNA load in the CSF may aid in situations where response assessment based on MRI 
alone remains challenging, including brain tumours treated with immunotherapy, and help clinical 
decision making.  
The situation is different for patients with brain metastases from solid tumours. For brain metastases 
from unknown primary tumours, either rapid neurosurgical intervention as clinically needed or initial 
work-up by chest abdomen CT or FDG-PET are standard procedures [78] whereas liquid biopsies have so 
far not assumed a role. However, patients with new brain lesions detected by neuroimaging who are 
known to suffer from a malignancy are not routinely sent for neurosurgical resection unless this is 
thought to be in the best interest of the patient, e.g., because there are concerns regarding the validity 
of the radiological diagnosis, or because the patient is neurologically symptomatic. In such 
circumstances, notably with tumours with targetable lesions or in patients pre-exposed to 
chemotherapy or targeted therapy, it may be of major interest to ascertain whether the molecular 
tumour profile has changed, to select the most appropriate treatment. In such scenarios molecular 
tumour profiling from ctDNA from the CSF could become most valuable. 
Similar considerations apply to patients with known leptomeningeal metastases, and targeted 
treatments are available for the major primary tumours associated with leptomeningeal metastasis: lung 
cancer, and breast cancer, and melanoma. The role of ctDNA in the CSF remains controversial if neither 
MRI nor routine CSF studies suggest the presence of leptomeningeal metastasis. In such situations, it 
can at present not be clarified whether ctDNA detected in the CSF signifies leptomeningeal tumour cell 
seeding. Thus, further studies are required to show that ctDNA in the CSF alone may justify treatment 
directed against leptomeningeal metastasis [79]. However the identification of the EGFR mutation or 
T790M in the CSF of patients with CNS metastases help guide the therapeutic decision in NSCLC 
patients. 
Regarding the current data, ctDNA should be explored for the diagnosis and in case of suspicion of 






Current data on ctDNA are mainly reported in small cohorts of patients, including sometimes different 
primary tumours. Analyses of large cohorts of patients should be performed. Technical issues such as 
the potential blood contamination in the CSF sample or the minimum time interval between surgery and 
CSF analysis for ctDNA have to be evaluated. Confirmation studies are needed to validate the role of 
ctDNA analysis for the diagnosis and follow-up of patients. Importantly, the feasibility of the CSF analysis 
in patients with brain tumours have to be considered when the lumbar puncture is contra-indicated due 
to risk of herniation related to the presentation of the space-occupying CNS tumours, or abnormal 
coagulation.  
Conclusions and future perspectives 
Increasing understanding of the genomic and epigenomic characteristics of primary brain tumours and 
brain and leptomeningeal metastases has uncovered the extraordinary complexity of these tumours [4, 
48, 80, 81]. Nevertheless, identifying biomarkers to assist in the diagnosis, prognosis, prediction of 
targeted therapy responses, serial monitoring and mechanisms of therapy resistance for patients with 
CNS malignancies [80] remains challenging, in part because of difficulties in accessing CNS tumour-
derived tissue. 
CNS malignancies demonstrate considerable spatial and temporal intratumour and inter-tumour 
heterogeneity. For patients with primary brain tumours or with brain metastases, identifying and 
monitoring brain-specific characteristics through CSF ctDNA may expedite the design of targeted 
therapies. Yet, no liquid circulating biomarkers have been validated and integrated into clinical practice 
for primary brain tumours or brain metastases. CSF ctDNA is a promising instrument to evaluate CNS 
malignancies in real-time and guide therapeutic management of patients.  
The treatment of human cancer has shifted towards a precision medicine paradigm, in which the 
selection of a targeted therapy will rely upon the genetic anomalies in individual patients. We predict 
that characterising brain tumours will be feasible using CSF ctDNA in the near future. In addition, 
combining plasma ctDNA with CSF ctDNA, morphologic analyses and imaging methods would ideally be 
complementary for patients with brain metastases and systemic disseminated disease. Thus, liquid 
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Comments to the Author 
The manuscript by Seoane et al. reviews the recent research on the use of cerebrospinal fluid 
(CSF) cell-free circulating tumour DNA (ctDNA) as diagnostic biomarker for patients with 
primary and secondary brain tumors. The most important comment is that expert analysis 
could be significantly strengthened throughout the manuscript so that the reader gains true 
understanding of where this field is. Below are some suggestions the authors can consider to 
further improve their manuscript. 
 
1) The review would benefit from a succinct paragraph or figure describing the ventricular 
system and CSF circulation, as well as brain-CSF interface/barrier. The assumption that CSF 
ctDNA assessment is superior to plasma ctDNA seems based on a small number of pilot studies 
(see Table). It is unclear whether higher yields of ctDNA seen with CSF are explained by unique 
physiological properties of this compartment or by the inclusion of patients with 
leptomeningeal disease. Moreover, it is unclear whether failure to assess plasma ctDNA in 
some studies is explained by the absence of plasma ctDNA in most patients or by limitations 
with currently available technologies (ie need of higher sequencing depth for assessing plasma 
ctDNA), as prior studies suggested the presence of circulating DNA even in patients with low-
grade gliomas (see PMID 23035067). 
 
We agree with the reviewer. We have now included a paragraph describing the CSF circulation 
as well as the brain-CSF barrier in the Introduction. We have also discussed the referee’s points 
stressing the limitations of the pilot studies and the current available technologies. We have 
cited PMID 23035067 and we have included in Table 1 the precise diagnoses of the analyzed 
cases showing the results of patients with tumours other than leptomeningeal metastasis. 
 
2) The review would benefit from a succinct paragraph or table summarizing the 
methodologies currently available, as well as the currently ongoing prospective studies 
evaluating CSF ctDNA in patients with primary and secondary brain tumors. 
 
We thank the reviewer for raising this point. We have now included a fragment about 
methodologies in the text, and a column describing the methodologies used by the different 
studies in Table 1. 
 
3) Data from patients with primary and secondary brain tumors is often presented together, 
which makes sometimes difficult to understand the potential of CSF ctDNA in each clinical 
situation. The review would likely benefit from slightly reorganizing the paragraphs to present 
separately the main messages from studies in primary vs secondary brain tumors. Moreover, 
data from patients with leptomeningeal disease should be presented separately as it is unclear 
whether findings in this population will be applicable to patients without leptomeningeal 
disease. 
 
We apologize for the lack of clarity. We have rewritten the manuscript following the reviewer 
recommendations and have now three new sections: Primary brain tumors, Brain metastases 
and Leptomeningeal metastases. Each of the sections including two subsections: Diagnostic 
considerations and Therapeutic considerations. 
 
 
4) The authors could discuss more thoroughly the strengths and limitations of the studies 
presented in their manuscript, especially when discussing pilot studies which need further 
validation. For instance, throughout the manuscript, the authors cite one of their studies (ref. 
20) without discussing the potential limitations of this work. The limitations of CSF puncture (ie 
patient’s refusal, contraindication) could also be mentioned. 
 
We agree with the reviewer. We have now included a section entitled: Current limitations, 
where we stated the lack of analyses of large cohorts of patients and the limitations of lumbar 
puncture, among other things. We have also included a column in Table 1 stating the number 
of patients in each study. 
 
5) In Table 1, it would be helpful to provide patient numbers for each study/disease group in 
the first column, and precise some diagnoses (eg "Primary brain and spinal cord tumours"). 
"CSF detection" should be replaced with "Method for CSF collection" 
 
We followed the reviewer’s comments and included the number of patients for each study, 
stated more precise diagnoses, and inserted a column for methods. 
 
6) The Figure does not provide much information and some parts seem speculative given the 
currently available data (eg lack of robust data suggesting that CSF ctDNA will allow discerning 
pseudoprogression from true progression in patients with gliomas). Would suggest removing 
or changing the title. 
 
We have changed the title of the figure by: ”Potential use of CSF ctDNA as a liquid biopsy for 
primary brain tumours and brain metastasis”. Moreover, we have deleted the concepts of 




Comments to the Author 
Seoane and colleagues did a quality review on liquid biopsy in neuro-oncology, particularly in 
the field of circulating tumor-derived cell free DNA in CSF. 
The authors have well presented the interest of CSF both in primary and secondary brain 
tumors. Two comments are suggested. 
1/ The authors propose that CSF could be used for diagnosis, particularly in case of 
contraindication to surgery, and treatment follow-up. The collection of CSF is at risk of rare but 
severe complications (cerebral involvement with bulky tumors, spinal bleeding, etc.) that could 
occur in the population of patients suffering from brain tumors. The authors should discuss 
this point. If the information is available, it could be of interest to know the amount of CSF 
needed for ctDNA analyzes and to specify the sequencing techniques in presented studies 
(Table 1). 
 
We thank the reviewer for raising this point. We have now included a section entitled: Current 
limitations, where we stated the limitations of lumbar puncture, among other things. We have 
also included a column in Table 1 stating the methodologies used in each study and inserted a 
paragraph in the Introduction describing the general methodology of CSF ctDNA analysis 
specifying the required CSF volume. 
 
 
2/ Regarding the impact of CSF ctDNA on survival, the authors should discuss the recent results 
of Juratli et al (Clin Cancer Research, 2018). 
 
We thank the reviewer for noting this interesting article. We have now discussed the Juratli et 



























Patient population Sequencing technologies 












4 glioblastoma, 2 medulloblastoma, and 17 brain 
metastases (from breast and NSCLC) 
Targeted capture massively parallel 
sequencing,  
digital droplet PCR 
Lumbar puncture, cerebral shunts, 
autopsy / 
58% 
CSF ctDNA is enriched in 
brain tumours and produces 
better results than plasma 
ctDNA. 
√ √ [15] 
35 primary brain and spinal cord tumours 
Targeted capture massively parallel 
sequencing,  
whole exome sequencing in four cases 
Cerebral shunts (during surgical 
procedure)/  
average of 4.8 mL (range = 0.75–10 
mL). 
74% 
All adjacent tumours to the 
CSF reservoir had CSF ctDNA 
detectable. 
-- -- [26] 
12 primary brain tumours and 41 brain metastases 
Targeted capture massively parallel 
sequencing  
Lumbar puncture and 1 sample 
Ommaya reservoir / 5 ml of CSF 
50-63% 
Drug-resistance mutations in 
patients whose CNS disease 
progresses during kinase 
inhibitor therapy is identified 
in CSF ctDNA. 
-- √ [27] 
a vestibular schwannoma, a meningioma, 5 brain 
metastases and  3 leptomeningeal metastases 
Targeted 
amplicon sequencing and digital PCR 
Lumbar puncture, cerebral shunts 
(during surgical procedure) / 1–10 mL 
of CSF 
85% 
Tumour mutations were 
detectable in the CSF ctDNA 
of patients with different 
types of brain tumours. 
√ -- [25] 
20 primary diffuse glioma tumours  
Targeted 
amplicon sequencing and digital PCR. 
Lumbar puncture prior to surgery; 2 
samples cisterna magna, 1 sample 
cerebral shunt / 2ml of CSF 
85% 
A sequencing platform to 
simultaneously test seven 
genes IDH1, IDH2, TP53, 
ATRX, TERT, H3F3A, 
HIST1H3B in the CSF ctDNA 
allowing the subclassification 
of diffuse glioma 
-- -- [28] 
38 TERT mutant glioblastoma  
(34 primary and 4 recurrent glioblastoma) 
Sequenced uni-directionally on an Ion 
Torrent PGM 
NGS system,  
digital droplet PCR 
Directly after opening the dura 
(durotomy), through dissection of the 
convexity subarachnoid 
space / 2-4 ml of CSF 
92.1% 
CSF ctDNA identifies 




13 glioma tumours 
Untargeted, low-coverage WGS (< 
0.4×) to detect SCNAs 
Lumbar puncture / 10 ml of CSF 38.4% 
Combining analyses of SCNAs 
with 
DNA fragmentation  
allows detection of ctDNA in 
CSF using sWGS data at low 
cost 
-- -- [29] 
Abbreviations: CNS, central nervous system; GBM, glioblastoma; LM, Leptomeningeal metastasis; NSCLC, non-small cell lung cancer; SCNAs, somatic copy number 
alterations; s-WGS, shallow whole-genome sequencing.  
 
